Thu 26 Jan 2012
Federal Consolidation of Lawsuits Against Hair Loss Drug Propecia (Finasteride)
Category: Hair Loss News , New Developments , Non Surgical Treatments , Propecia (Finasteride)
Although it’s been proven safe and effective for treating male pattern baldness in several research trials, many hair loss sufferers still insist that the hair restoration drug Propecia (finasteride) causes irreversible sexual dysfunction. Furthermore, these same individuals claim Merck Pharmaceuticals, the makers of Propecia, failed to adequately warn patients about the potential long-term sexual side effects associated with the drug.
As a result, over 51 different class action lawsuits have been filed against Merck Pharmaceuticals within the past several years. Although all cases focus on the allegedly permanent sexual side effects, each differs slightly and was scheduled for a unique day in court. However, Merck Pharmaceuticals recently altered the legal situation by deciding these individual complaints should be consolidated into one lawsuit and evaluated during a single proceeding.
Because 41 of the 53 complaints have been filed in New Jersey, Merck recommends the single trial take place in a New Jersey courtroom. A hearing, to determine whether the consolidation will occur, is scheduled to take place on March 29th, 2012 in San Diego, California.
Legal experts claim the consolidated proceeding would help prevent contradictory decisions and unnecessary pretrial rulings.
In an interesting turn, the official Propecia website is “down” and contains the following message: Thank you for visiting propecia.com, this website is currently not available; You are encouraged to report negative side effects of prescription drugs to the FDA.
While it’s uncertain whether the website content is related to the current lawsuits, many hair loss patients cannot ignore the coincidental timing.











